Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Mouse lysine catabolism to aminoadipate occurs primarily through the saccharopine pathway; implications for pyridoxine dependent epilepsy (PDE)

Texto completo
Autor(es):
Pena, Izabella Agostinho ; Marques, Lygia Azevedo ; Laranjeira, Angelo B. A. ; Yunes, Jose A. ; Eberlin, Marcos N. ; MacKenzie, Alex ; Arruda, Paulo
Número total de Autores: 7
Tipo de documento: Artigo Científico
Fonte: BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE; v. 1863, n. 1, p. 121-128, JAN 2017.
Citações Web of Science: 10
Resumo

Lysine is catabolized in mammals through the saccharopine and pipecolate pathways the former is mainly hepatic and renal, and the latter is believed to play a role in the cerebral lysine oxidation. Both pathways lead to the formation of aminoadipic semialdehyde (AASA) that is then oxidized to aminoadipate (AAA) by antiquitin (ALDH7A1). Mutations in the ALDH7A1 gene result in the accumulation of AASA and its cyclic form, piperideine-6-carboxylate (P6C), which causes pyridoxine-dependent epilepsy (PDE). P6C reacts with pyridoxal 5'-phosphate (PLP) causing its inactivation. Here, we used liquid chromatography-mass spectrometry to investigate lysine catabolism in mice injected with lysine labelled at either its nitrogen epsilon (epsilon-N-15) or nitrogen alpha (alpha-N-15). Analysis of epsilon-N-15 and alpha-N-15 lysine catabolites in plasma, liver and brain suggested the saccharopine as the main pathway for AAA biosynthesis. Although there was evidence for upstream cerebral pipecolate pathway activity, the resulting pipecolate does not appear to be further oxidized into AASA/P6C/AAA. By far the bulk of lysine degradation and therefore, the primary source of lysine catabolites are hepatic and renal. The results indicate that the saccharopine pathway is primarily responsible for body's production of AASA/P6C The centrality of the saccharopine pathway in whole body lysine catabolism opens new possibilities of therapeutic targets for PDE. We suggest that inhibition of this pathway upstream of AASA/P6C synthesis may be used to prevent its accumulation benefiting PDE patients. Inhibition of the enzyme aminoadipic semialdehyde synthase, for example, could constitute a new strategy to treat PDE and other inherited diseases of lysine catabolism. (C) 2016 Elsevier B.V. All rights reserved. (AU)

Processo FAPESP: 10/50114-4 - O papel da via da sacaropina em diversos modelos biológicos
Beneficiário:Paulo Arruda
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 13/23920-8 - Técnicas modernas em espectrometria de massas e novas aplicações em ciências: química, bioquímica, materiais, forense, medicina, alimentos, farmácia e veterinária
Beneficiário:Lygia de Azevedo Marques
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 12/00235-5 - Mecanismos de indução da via da sacaropina em células humanas
Beneficiário:Izabella Agostinho Pena
Linha de fomento: Bolsas no Brasil - Doutorado Direto